Crinetics Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
Checking your notes…
(in thousands, except per share data)
| September 30,2025 | December 31,2024 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $110,901 | $264,545 |
| Restricted cash | 500 | 500 |
| Investment securities, amortized cost of $979,147 at September 30, 2025 and $1,088,561 at December 31, 2024 | 981,390 | 1,089,524 |
| Prepaid expenses and other current assets | 28,484 | 20,819 |
| Total current assets | 1,121,275 | 1,375,388 |
| Property and equipment, net | 14,377 | 12,068 |
| Operating lease right-of-use assets | 41,147 | 43,507 |
| Restricted cash, net of current portion | 800 | 800 |
| Prepaid expenses and other assets, net of current portion | 18,432 | 2,829 |
| TOTAL ASSETS | $1,196,031 | $1,434,592 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued expenses | $33,674 | $21,469 |
| Accrued compensation and related expenses | 32,398 | 28,887 |
| Deferred revenue | 1,642 | 2,176 |
| Operating lease liabilities | 6,441 | 7,152 |
| Total current liabilities | 74,155 | 59,684 |
| Operating lease liabilities, non-current | 42,703 | 44,570 |
| Deferred revenue, non-current | 4,110 | 4,704 |
| Other liabilities | 2,894 | 829 |
| TOTAL LIABILITIES | 123,862 | 109,787 |
| Commitments and contingencies (Note 6) | ||
| STOCKHOLDERS’ EQUITY | ||
| Preferred stock, $0.001 par; 10,000 shares authorized; no shares issued or outstanding at September 30, 2025 or December 31, 2024 | — | — |
| Common stock and paid-in capital, $0.001 par; 200,000 shares authorized; 94,548 shares issued and outstanding at September 30, 2025; 92,926 shares issued and outstanding at December 31, 2024 | 2,364,699 | 2,275,952 |
| Accumulated other comprehensive income | 2,194 | 963 |
| Accumulated deficit | (1,294,612) | (952,110) |
| Stock held in trust | (112) | — |
| TOTAL STOCKHOLDERS’ EQUITY | 1,072,169 | 1,324,805 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $1,196,031 | $1,434,592 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.